Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 267 publications.
Skip to main content
Brufsky AM, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg E, Makari D, Candrilli SD, Goyal RK, Rugo HS. Overall survival with palbociclib and aromatase inhibitor versus aromatase inhibitor alone in older patients with HR+/HER2− metastatic breast cancer. Cancer Med. 2025 Apr;14(7):e70719. doi: 10.1002/cam4.70719
Perreault S, Hukin J, Erker C, Silayuv EB, Hamilton MA, Kim Y, Jimenez MI, Candrilli SD. Treatment patterns and healthcare resource utilization of pediatric patients with neurofibromatosis type 1 and unresectable plexiform neurofibroma in Canada. Poster presented at the 2024 Global NF Conference; June 20, 2024. Brussels, Belgium.
Goyal RK, Candrilli SD, Abughosh S, Chen H, Holmes HM, Johnson ML. Social determinants of health and other predictors in initiation of treatment with CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer. Cancers. 2024 Jun 7;16(12):2168. doi: 10.3390/cancers16122168
Brufsky A, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg L, Makari D, Candrilli S, Goyal R, Rugo H. Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: a SEER-Medicare analysis. Poster presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2024. Chicago, IL.
Stirnadel-Farrant HA, Xu X, Kwiatek J, Jain P, Meyers J, Candrilli S, Mines D, Datto CJ. Characteristics, treatment patterns, healthcare resource utilization and costs in patients with bullous pemphigoid: a retrospective analysis of US health insurance claims data. J Am Acad Dermatol. 2023 Dec;13:117-25. doi: 10.1016/j.jdin.2023.04.014
Goyal RK, Candrilli SD, Abughosh SM, Chen H, Holmes HM, Johnson ML. Social Determinants of Health (SDoH) and other predictors in treatment initiation with CDK4/6 inhibitors in Medicare patients with HR+/HER2– Metastatic Breast Cancer (MBC). Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S286. doi: 10.1016/j.jval.2023.09.1502
Ghaswalla P, Hitchens A, Candrilli SD, Carrico J, Hicks KA, Wilson E, Mehta D, Panozzo CA. Prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19 in adults in the United States, 2017-2018. Poster presented at the IDWeek 2023; October 12, 2023. Boston, MA.
Singer D, Dubois de Gennes C, Brabant Y, Aris E, Molnar D, Candrilli S, La E. Clinical and economic burden of hospitalized respiratory syncytial virus cases among adults aged 50 years and older with chronic conditions. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S86-7. doi: 10.18553/jmcp.2023.29.10-a.s1
Shapouri S, Candrilli S, Miles L, Simpson A, Guittari C. Real-world evidence for risdiplam-treated adults with spinal muscular atrophy: a multicenter study. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S130. doi: 10.18553/jmcp.2023.29.10-a.s1
Bellmunt J, Chang J, Pavilack-Kirker M, Cappelleri JC, Costa N, Esterberg E, Kearney M, Hitchens A, Candrilli SD, Ajmera M. Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multi-country retrospective medical chart review. Clin Genitourin Cancer. 2023 Aug;21(4):459-66. doi: 10.1016/j.clgc.2023.03.011
Shapouri S, Candrilli S, Miles L, Simpson A, Guittari CJ. Real-world treatment with risdiplam in adults with SMA: a multicenter study. Poster presented at the 2023 Annual SMA Research & Clinical Care Meeting; June 28, 2023. Orlando, FL.
Stirnadel-Farrant HA, Xu X, Kwiatek J, Jain P, Meyers J, Candrilli S, Mines D, Datto CJ. Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: a retrospective analysis of US health insurance claims data. JAAD Int. 2023 Jun 9;13:117-25. doi: 10.1016/j.jdin.2023.04.014
Aris E, Brabant Y, La E, Candrilli S, Molnar D. Health care resource use and medical costs attributable to respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States: a retrospective claims database analysis. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S124. doi: 10.1016/j.jval.2023.03.657
Kaul S, Gosmanova EO, Castriota F, Hitchens A, Candrilli S, Parikh R, Esterberg E, Ayodele O. Recent trends in hypoparathyroidism-related inpatient and emergency department admissions and costs in the United States. J Endocr Soc. 2023 Apr 18;7(5):bvad050. doi: 10.1210/jendso/bvad050.
Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: a SEER-Medicare population-based study. Cancer. 2023 Apr 1;129(7):1051-63. doi: 10.1002/cncr.34675
Goyal RK, Holmes HM, Chen H, Abughosh S, Candrilli SD, Johnson ML. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb;198(1):159-66. doi: 10.1007/s10549-022-06845-4
Xu X, Kwiatek J, Chehade M, Aceves S, Maslova E, Kielar D, Stirnadel-Farrant H, Meyers J, Candrilli S, Katial R. Characteristics of and healthcare cost drivers among U.S. patients with eosinophilic esophagitis with high versus non-high all-cause costs: an analysis of insurance claims data. Poster presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting; October 24, 2022. Charlotte, NC.
Xu X, Datto C, Kwiatek J, Meyers J, Candrilli S, Mines D, Stirnadel-Farrant H. Comparison of healthcare resource utilization and costs in patients with and without Bullous Pemphigoid: a retrospective analysis of US health insurance claims data. Poster presented at the ISPOR 2022 Conference; May 18, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Brown J, Liepa AM, Bapat B, Madhwani S, Lorenzen S, Garcia-Foncillas J, Candrilli S, Kaye JA. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. Eur J Cancer Care (Engl). 2020 Mar;29(2):e13213. doi: 10.1111/ecc.13213
Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP. Corrigendum to: Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infect Dis. 2020 Jan 13;7(1):ofz536. doi: 10.1093/ofid/ofz536
Stull K, Esterberg E, Ajmera M, Candrilli S, Kitt TM, Spalding JR, Patel VP. Use of antifungals and outcomes among inpatients at risk of invasive aspergillosis or mucormycosis in the USA: a retrospective cohort study. Infect Dis Ther. 2019 Dec;8(4):641-55. doi: 10.1007/s40121-019-00267-4
Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP. Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infect Dis. 2019 Nov;6(11):ofz446. doi: 10.1093/ofid/ofz446
Candrilli SD, Kurosky SK. The response to and cost of meningococcal disease outbreaks in university campus settings: a case study in Oregon, United States. 2019. Research Triangle Park: RTI Press. doi: 10.3768/rtipress.2019.rr.0034.1910
Meyers J, Sinha A, Samant S, Candrilli S. The economic burden of congenital cytomegalovirus disease in the first year of life: a retrospective analysis of health insurance claims data in the United States. Clin Ther. 2019 Jun;41(6):1040-1056. doi: 10.1016/j.clinthera.2019.04.022
Trantham L, Sikirica MV, Candrilli S, Benson VS, Mohan D, Neil D, Joshi AV. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis. J Med Econ. 2019 Apr;22(4):319-27. doi: 10.1080/13696998.2018.1563414.
Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Costs of herpes zoster complications in older adults: a cohort study of US claims database. Vaccine. 2019 Feb 21;37(9):1235-44. doi: 10.1016/j.vaccine.2018.11.079
Candrilli SD, Kurosky S. Recent trends in meningococcal disease-related hospitalization in the United States. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson B, Levin M. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Vaccine. 2018 Oct 29;36(45):6810-8. doi: 10.1016/j.vaccine.2018.08.080
Rajagopalan K, Candrilli SD, Ajmera M. Impact of antiepileptic drug-treatment burden on health-care-resource utilization and costs. Clinicoecon Outcomes Res. 2018 Oct 16;2018(10):619-27. doi: 10.2147/CEOR.S180913
Sinha A, Meyers J, Samant S, Trantham L, Candrilli S. The incremental burden of congenital cytomegalovirus in the first year of life: a retrospective case-control analysis of Medicaid and commercial claims data. Presented at the 2018 CMV Public Health and Policy Conference; September 25, 2018. Burlington, VT.
Mytelka DS, Nagar SP, D'yachkova Y, La EM, Kaye JA, Candrilli SD, Kasper B, Lopez-Martin JA, Lorenzo M. Health care resource utilization and costs among adult patients with advanced soft tissue sarcoma: a retrospective medical record review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018 Sep 12;2018:2020591. doi: 10.1155/2018/2020591
Nagar S, Mytelka D, Candrilli SD, D'yachkova Y, Lorenzo M, Kasper B, Lopez-Martin J, Kaye JA. Treatment patterns and survival among adult patients with advanced soft tissue sarcoma: a retrospective medical record review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018 May 24;2018. doi: 10.1155/2018/5467057
Parikh RC, Lorenzo M, Hess LM, Candrilli SD, Nicol S, Kaye JA. Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas. Clin Sarcoma Res. 2018 May 3;8:8. doi: 10.1186/s13569-018-0094-x
Saltus CW, Calingaert B, Candrilli S, Lorenzo M, D’yachkova Y, Otto T, Wagner U, Kaye JA. Epidemiology of adult soft-tissue sarcomas in Germany. Sarcoma. 2018 Apr 4;2018:5671926. doi: 10.1155/2018/5671926
Parikh R, Clancy Z, Candrilli S, Parikh K. Administrative data algorithms to identify diagnosis and treatment-related measures in patients with multiple myeloma: a validation study. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-2):S29.
Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Support Care Cancer. 2018 Feb;26(2):539-48. doi: 10.1007/s00520-017-3863-9
Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018 Jan;384(2018):96-103. doi: 10.1016/j.jns.2017.11.022
Parikh RC, McLaurin KK, Margulis AV, Mauskopf J, Ambrose CS, Pavilack M, Candrilli SD. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017 Dec;6(4):477-86. doi: 10.1007/s40121-017-0167-9
Candrilli S, Trantham L. Recent trends in congenital cytomegalovirus-related hospitalization in the United States. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland.
Rausch D, Levin MJ, Meyers JL, Candrilli SD, Yan S, Krishnarajah G, Patterson B. Cost of herpes zoster and related complications in patients with immunocompromising conditions aged ≥50 years: a US insurance claims data analysis. Presented at the AAFP Family Medicine Experience; September 2017. San Antonio, TX.
Meyers JL, Madhwani S, Rausch D, Candrilli SD, Krishnarajah G, Yan S. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States. Hum Vaccin Immunother. 2017 Aug 3;13(8):1861-72.
Rausch DA, Levin M, Meyers J, Candrilli S, Yan S, Krishnarajah G, Patterson B. Cost of diagnosed herpes zoster complications in patients age ≥50 years: a US claims data analysis. Poster presented at the IAGG 2017 World Congress; July 23, 2017. San Francisco, CA. [abstract] Innov Aging. 2017 Jul; 1(Suppl 1):902. doi: 10.1093/geroni/igx004.3234
Bell K, Meyers J, Candrilli SD, Ajmera MR. Characteristics and costs of patients with type 2 diabetes augmenting metformin with dapagliflozin versus glipizide: an analysis of commercial claims data. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A169.
Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039
Korsnes JS, Goodwin BB, Murray M, Candrilli SD. Antiretroviral treatment switching and its association with economic outcomes and adverse treatment effects among commercially insured and Medicaid-enrolled patients with HIV in the United States. Ann Pharmacother. 2016 Dec;50(12):989-1000.